Business Wire06.28.19
Intersect ENT Inc., a company dedicated to transforming care for patients with ear, nose and throat conditions, announced the appointment of Thomas (“Tom”) A. West as president and CEO, effective July 22, 2019. He will also join the Intersect ENT Board of Directors at that time, and Kieran Gallahue will remain in his role as Executive Chairman of the Board.
West has served as Division President, Diagnostics Solutions at Hologic, Inc. since October 2014. Under Tom’s leadership, Hologic delivered consistent, above-market revenue growth rates in the domestic and international diagnostics business, achieving over $1.1 billion in worldwide diagnostics sales and reversing previous declines. Molecular Diagnostics, the division’s largest segment, grew at over eight percent per year—nearly two times the rate of the market—during his tenure. West also oversaw a steady cadence of innovation, yielding multiple FDA approvals across 11 consecutive quarters since 2016. Prior to Hologic, he held various roles of increasing responsibility at Johnson & Johnson, including serving as Worldwide Vice President of Strategy and Business Development for Johnson & Johnson’s Diabetes Solutions Companies. Previously, West served as President of LifeScan North America and as President of LifeScan EMEA. While leading LifeScan EMEA, he tripled the business in the span of four years. West earned a Bachelor’s degree in politics and economics from Princeton University and a Master of Business Administration from the Wharton School at the University of Pennsylvania.
“Tom is a proven healthcare leader bringing more than two decades of medical technology experience to Intersect ENT. We look forward to leveraging his deep knowledge of and expertise in accelerating growth through commercial execution, product innovation and the building of strong, integrated teams,” said Gallahue. “The Board and I are impressed with Tom’s strategic insights and established track record of strong execution and successful product commercialization. We believe Tom’s leadership will be a great benefit to us as we continue to advance our products in the marketplace, drive growth across our portfolio and deliver on our goal of making localized drug delivery the standard of care for patients suffering from chronic sinusitis.”
“I’m thrilled to join Intersect ENT at this time and look forward to building on the company’s history of innovation to drive accelerated growth via strong execution and with consistent financial and operational performance,” said West. “I am excited to join the Intersect ENT team in our mission of transforming care in the ear, nose and throat (ENT) specialty and extend the company’s leadership in innovation in localized drug delivery. With focused execution across both Intersect ENT’s commercialized products and pipeline of innovative, clinically meaningful therapies, I am confident that we can build an even stronger foundation for future growth as we enhance value to our shareholders.”
The company also today announced that Jeryl (“Jeri”) Hilleman, CFO, will step down as part of a planned transition at the beginning of 2020 so that she can focus on board responsibilities. The Board has initiated a search process to identify Intersect ENT’s next CFO.
“We want to express our deep appreciation for Jeri’s many and significant accomplishments over the years, and are deeply grateful for her commitment to ensure a seamless transition throughout this planned process,” said Gallahue. “Jeri has contributed broadly to the organization over the years, and we wish her well in the next stage of her career.”
West has served as Division President, Diagnostics Solutions at Hologic, Inc. since October 2014. Under Tom’s leadership, Hologic delivered consistent, above-market revenue growth rates in the domestic and international diagnostics business, achieving over $1.1 billion in worldwide diagnostics sales and reversing previous declines. Molecular Diagnostics, the division’s largest segment, grew at over eight percent per year—nearly two times the rate of the market—during his tenure. West also oversaw a steady cadence of innovation, yielding multiple FDA approvals across 11 consecutive quarters since 2016. Prior to Hologic, he held various roles of increasing responsibility at Johnson & Johnson, including serving as Worldwide Vice President of Strategy and Business Development for Johnson & Johnson’s Diabetes Solutions Companies. Previously, West served as President of LifeScan North America and as President of LifeScan EMEA. While leading LifeScan EMEA, he tripled the business in the span of four years. West earned a Bachelor’s degree in politics and economics from Princeton University and a Master of Business Administration from the Wharton School at the University of Pennsylvania.
“Tom is a proven healthcare leader bringing more than two decades of medical technology experience to Intersect ENT. We look forward to leveraging his deep knowledge of and expertise in accelerating growth through commercial execution, product innovation and the building of strong, integrated teams,” said Gallahue. “The Board and I are impressed with Tom’s strategic insights and established track record of strong execution and successful product commercialization. We believe Tom’s leadership will be a great benefit to us as we continue to advance our products in the marketplace, drive growth across our portfolio and deliver on our goal of making localized drug delivery the standard of care for patients suffering from chronic sinusitis.”
“I’m thrilled to join Intersect ENT at this time and look forward to building on the company’s history of innovation to drive accelerated growth via strong execution and with consistent financial and operational performance,” said West. “I am excited to join the Intersect ENT team in our mission of transforming care in the ear, nose and throat (ENT) specialty and extend the company’s leadership in innovation in localized drug delivery. With focused execution across both Intersect ENT’s commercialized products and pipeline of innovative, clinically meaningful therapies, I am confident that we can build an even stronger foundation for future growth as we enhance value to our shareholders.”
The company also today announced that Jeryl (“Jeri”) Hilleman, CFO, will step down as part of a planned transition at the beginning of 2020 so that she can focus on board responsibilities. The Board has initiated a search process to identify Intersect ENT’s next CFO.
“We want to express our deep appreciation for Jeri’s many and significant accomplishments over the years, and are deeply grateful for her commitment to ensure a seamless transition throughout this planned process,” said Gallahue. “Jeri has contributed broadly to the organization over the years, and we wish her well in the next stage of her career.”
